US6743777B1
(en)
*
|
1992-03-19 |
2004-06-01 |
Eli Lilly And Company |
Cyclic peptide antifungal agents and process for preparation thereof
|
US7091311B2
(en)
*
|
1996-06-07 |
2006-08-15 |
Smithkline Beecham Corporation |
Peptides and compounds that bind to a receptor
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
EP1124961B9
(en)
*
|
1998-10-23 |
2010-07-21 |
Kirin-Amgen Inc. |
Thrombopoietic compounds
|
WO2000047740A2
(en)
*
|
1999-02-12 |
2000-08-17 |
Amgen Inc. |
Tnf-related proteins
|
CN100335122C
(zh)
*
|
1999-03-03 |
2007-09-05 |
伊莱利利公司 |
含有成胶束表面活性剂的棘白菌素药物制剂
|
AU772633B2
(en)
*
|
1999-03-03 |
2004-05-06 |
Eli Lilly And Company |
Echinocandin/carbohydrate complexes
|
JP2003503426A
(ja)
|
1999-07-02 |
2003-01-28 |
ジェネンテック・インコーポレーテッド |
FVIIaアンタゴニスト
|
ATE330967T1
(de)
|
1999-07-02 |
2006-07-15 |
Genentech Inc |
An her2 bindende peptidverbindungen
|
AU782496B2
(en)
*
|
1999-07-13 |
2005-08-04 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
WO2001009165A2
(en)
*
|
1999-07-29 |
2001-02-08 |
The Johns Hopkins University |
ACTIVATION OF PEPTIDE PRODRUGS BY hK2
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6808902B1
(en)
*
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
AU5717301A
(en)
|
2000-04-21 |
2001-11-07 |
Amgen Inc |
Apo-ai/aii peptide derivatives
|
AU2001259432B2
(en)
*
|
2000-05-03 |
2005-04-21 |
Amgen Inc. |
Modified peptides, comprising an FC domain, as therapeutic agents
|
US20020090646A1
(en)
*
|
2000-05-03 |
2002-07-11 |
Amgen Inc. |
Calcitonin-related molecules
|
WO2001087977A2
(en)
*
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
US7259146B2
(en)
|
2000-05-26 |
2007-08-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Neuroprotective peptides
|
CA2410453A1
(en)
*
|
2000-05-26 |
2001-12-06 |
Ortho-Mcneil Pharmaceutical, Inc. |
Neuroprotective peptides
|
ES2386258T3
(es)
*
|
2000-06-02 |
2012-08-14 |
Eidgenössische Technische Hochschule Zürich |
Relaciones de adición conjugadas para la entrega controlada de compuestos farmacéuticamente activos
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
ATE431405T1
(de)
*
|
2000-09-05 |
2009-05-15 |
Amgen Inc |
Tnf-rezeptor-ähnliche moleküle und deren anwendungen
|
DE60136656D1
(de)
*
|
2000-12-05 |
2009-01-02 |
Alexion Pharma Inc |
Rationell entworfene Antikörper
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
AU2003295623B2
(en)
*
|
2000-12-05 |
2008-06-05 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7491702B2
(en)
*
|
2001-04-18 |
2009-02-17 |
The Open University |
Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
|
US7622446B2
(en)
*
|
2001-04-18 |
2009-11-24 |
The Open University |
Polypeptides, derivatives and uses thereof
|
ES2387546T3
(es)
|
2001-05-11 |
2012-09-25 |
Amgen Inc. |
Péptidos y moléculas relacionadas que se unen a TALL-1
|
ES2907826T3
(es)
*
|
2001-06-26 |
2022-04-26 |
Amgen Inc |
Anticuerpos para OPGL
|
MXPA04003057A
(es)
|
2001-10-04 |
2005-06-20 |
Immunex Corp |
Proteina 4 de enlace ul16.
|
MX339524B
(es)
*
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7737260B2
(en)
*
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Protein complex using an immunoglobulin fragment and method for the preparation thereof
|
US20030113270A1
(en)
*
|
2001-12-14 |
2003-06-19 |
Clark Abbot F. |
Vasoactive intestinal peptides for glaucomatous retinopathy
|
US7056535B2
(en)
*
|
2001-12-20 |
2006-06-06 |
Kimberly-Clark Worldwide, Inc. |
Triggered release from proteinoid microspheres
|
US20030138975A1
(en)
*
|
2001-12-20 |
2003-07-24 |
Kimberly-Clark Worldwide, Inc. |
Diagnostic signal amplification with proteinoid microspheres
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
CA2480121C
(en)
|
2002-03-27 |
2012-02-28 |
Immunex Corporation |
Methods for increasing polypeptide production
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US7718776B2
(en)
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
US6991800B2
(en)
*
|
2002-06-13 |
2006-01-31 |
Vicuron Pharmaceuticals Inc. |
Antifungal parenteral products
|
AU2003280130B2
(en)
*
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
EP1394180B1
(de)
*
|
2002-08-06 |
2008-07-16 |
AplaGen GmbH |
Synthetische Mimetika von physiologischen Bindungsmolekülen
|
EP1527096A2
(en)
*
|
2002-08-06 |
2005-05-04 |
AplaGen GmbH |
Binding molecules
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
MEP32508A
(en)
|
2002-09-06 |
2010-10-10 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
PL217085B1
(pl)
*
|
2002-09-11 |
2014-06-30 |
Fresenius Kabi Gmbh |
Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania koniugatu hydroksyalkiloskrobi i polipeptydu, zastosowanie koniugatu hydroksyalkiloskrobi i polipeptydu oraz kompozycja farmaceutyczna koniugatu hydroksyalkiloskrobi i polipeptydu
|
WO2004026332A1
(en)
|
2002-09-18 |
2004-04-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Methods of increasing platelet and hematopoietic stem cell production
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
EP2364996B1
(en)
|
2002-09-27 |
2016-11-09 |
Xencor Inc. |
Optimized FC variants and methods for their generation
|
US20040149235A1
(en)
*
|
2002-10-04 |
2004-08-05 |
Pogue Albert S. |
Apparatus and method for removal of waste from animal production facilities
|
NZ570811A
(en)
|
2002-11-09 |
2009-11-27 |
Immunocore Ltd |
T cell receptor display
|
KR20150013350A
(ko)
*
|
2002-12-20 |
2015-02-04 |
암겐 인코포레이티드 |
미오스타틴을 저해하는 결합제
|
US7125849B2
(en)
*
|
2003-01-14 |
2006-10-24 |
The Scripps Research Institute |
Peptide-based angiogenesis inhibitors and methods of use thereof
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
PL377560A1
(pl)
*
|
2003-02-06 |
2006-02-06 |
Merck Patent Gmbh |
Sulfonamidy peptydowe
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
US20050281829A1
(en)
*
|
2003-05-06 |
2005-12-22 |
Hehir Cristina A T |
Fc chimeric proteins with anti-HIV drugs
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2004100882A2
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
PT1624891E
(pt)
*
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
EP2336162A1
(en)
*
|
2003-05-12 |
2011-06-22 |
Affymax, Inc. |
Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
|
US7919118B2
(en)
*
|
2003-05-12 |
2011-04-05 |
Affymax, Inc. |
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
|
ES2395413T3
(es)
*
|
2003-05-12 |
2013-02-12 |
Affymax, Inc. |
Péptidos que se unen al receptor de eritropoyetina
|
SI1629007T1
(sl)
|
2003-05-12 |
2009-10-31 |
Affymax Inc |
Novi peptidi, ki se veĹľejo na eritropoetinski receptor
|
JP4866238B2
(ja)
*
|
2003-06-20 |
2012-02-01 |
シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー |
B型肝炎ウィルスの新規の表面タンパク質(HBsAg)変異体
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
ES2383328T3
(es)
|
2003-07-25 |
2012-06-20 |
Amgen, Inc |
Métodos relacionados con LDCAM y CRTAM
|
WO2005014655A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
ATE447611T1
(de)
|
2003-08-18 |
2009-11-15 |
Univ California |
Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
|
US8158589B2
(en)
|
2003-08-22 |
2012-04-17 |
Proyecto Biomedicine Cima, S.L. |
Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
|
ES2304069B1
(es)
*
|
2003-08-22 |
2009-08-12 |
Proyecto De Biomedicina Cima, S.L. |
Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
UA89481C2
(uk)
*
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US20060127404A1
(en)
*
|
2003-09-30 |
2006-06-15 |
Chichi Huang |
Hinge core mimetibodies, compositions, methods and uses
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
EP1691763A4
(en)
|
2003-12-12 |
2008-03-12 |
Genencor Int |
CAB MOLECULES
|
JP2008505607A
(ja)
*
|
2004-01-29 |
2008-02-28 |
ジェネンテック・インコーポレーテッド |
Bcmaの細胞外ドメインの変異体とその使用法
|
CN102302787A
(zh)
*
|
2004-03-11 |
2012-01-04 |
费森尤斯卡比德国有限公司 |
羟烷基淀粉和蛋白质的接合物
|
CA2558738C
(en)
|
2004-03-11 |
2013-02-05 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
HUE040595T2
(hu)
*
|
2004-04-02 |
2019-03-28 |
Swedish Orphan Biovitrum Ab Publ |
Eljárás IL-1ra aggregációjának csökkentésére
|
US20050222040A1
(en)
*
|
2004-04-05 |
2005-10-06 |
Blm Group, Inc. |
Vertebrate peptide modulators of lipid metabolism
|
DE602005023138D1
(de)
|
2004-04-15 |
2010-10-07 |
Genencor Int |
Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
|
JP2005309295A
(ja)
*
|
2004-04-26 |
2005-11-04 |
Nec Corp |
光増幅素子、光増幅装置および光増幅システム
|
US7678767B2
(en)
|
2004-06-16 |
2010-03-16 |
Pneumrx, Inc. |
Glue compositions for lung volume reduction
|
US7553810B2
(en)
*
|
2004-06-16 |
2009-06-30 |
Pneumrx, Inc. |
Lung volume reduction using glue composition
|
US7468350B2
(en)
|
2004-06-16 |
2008-12-23 |
Pneumrx, Inc. |
Glue composition for lung volume reduction
|
US7608579B2
(en)
*
|
2004-06-16 |
2009-10-27 |
Pneumrx, Inc. |
Lung volume reduction using glue compositions
|
US20050281739A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Glen Gong |
Imaging damaged lung tissue using compositions
|
US20050281740A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Glen Gong |
Imaging damaged lung tissue
|
US20050281798A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Glen Gong |
Targeting sites of damaged lung tissue using composition
|
KR101100059B1
(ko)
|
2004-06-30 |
2011-12-29 |
넥타르 테라퓨틱스 |
중합체인자 ix 부분의 접합체
|
US7766938B2
(en)
|
2004-07-08 |
2010-08-03 |
Pneumrx, Inc. |
Pleural effusion treatment device, method and material
|
US8143380B2
(en)
*
|
2004-07-08 |
2012-03-27 |
Amgen Inc. |
Therapeutic peptides
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
WO2007001332A2
(en)
*
|
2004-08-04 |
2007-01-04 |
University Of Massachusetts |
Anti-pathogen immunoadhesins
|
US20060210542A1
(en)
*
|
2004-08-16 |
2006-09-21 |
Yurkow Edward J |
Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
DK1797127T3
(en)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
EP1799700A4
(en)
*
|
2004-09-27 |
2009-02-11 |
Centocor Inc |
SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
|
AU2005305182A1
(en)
*
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind BAFF and/or APRIL
|
CN101142234A
(zh)
*
|
2004-11-11 |
2008-03-12 |
阿费麦克斯公司 |
结合红细胞生成素受体的新肽
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070110760A1
(en)
*
|
2005-01-14 |
2007-05-17 |
Monroe John G |
Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
|
WO2006078914A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Washington University In St. Louis |
Compounds having rd targeting motifs
|
EP1854807A4
(en)
*
|
2005-02-18 |
2009-04-01 |
Univ Tokushima |
A LIPID DERIVATIVE CONTAINING A POLYOXYALKYLENE CHAIN AND A LIPID FILM STRUCTURE CONTAINING SUCH A DERIVATIVE
|
US7723472B2
(en)
*
|
2005-02-28 |
2010-05-25 |
The Regents Of The University Of California |
Extracellular matrix binding chimeric proteins and methods of use thereof
|
US20060241040A1
(en)
*
|
2005-04-06 |
2006-10-26 |
Alberto Visintin |
Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2006116076A2
(en)
|
2005-04-28 |
2006-11-02 |
Genencor International, Inc. |
Tab molecules
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
US7566456B2
(en)
*
|
2005-06-23 |
2009-07-28 |
Haiming Chen |
Allergen vaccine proteins for the treatment and prevention of allergic diseases
|
CA2648732A1
(en)
*
|
2005-06-23 |
2006-12-28 |
Aplagen Gmbh |
Supravalent compounds
|
CN103172739A
(zh)
*
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
NZ625807A
(en)
|
2005-07-18 |
2015-11-27 |
Amgen Inc |
Human anti-b7rp1 neutralizing antibodies
|
ES2539250T3
(es)
|
2005-07-25 |
2015-06-29 |
Emergent Product Development Seattle, Llc |
Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
|
EP1916997B1
(en)
|
2005-08-05 |
2018-04-18 |
Amgen Inc. |
Stable aqueous protein pharmaceutical formulations and their preparation
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CN101258164B
(zh)
*
|
2005-08-16 |
2013-05-01 |
韩美科学株式会社 |
用于大量生产缺失起始甲硫氨酸残基的免疫球蛋白Fc区的方法
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2620886C
(en)
|
2005-08-31 |
2017-03-14 |
The Regents Of The University Of California |
Cellular libraries of peptide sequences (clips) and methods of using the same
|
KR100780405B1
(ko)
*
|
2005-08-31 |
2007-11-28 |
재단법인서울대학교산학협력재단 |
알파 나선형 펩티드를 이용한 rna 특이적 결합 펩티드탐색 방법
|
EP1762250A1
(en)
*
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
|
JP2009510102A
(ja)
*
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
免疫調節組成物およびその使用
|
JP2009510002A
(ja)
|
2005-09-30 |
2009-03-12 |
アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
反発誘導分子(rgm)タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US8445642B1
(en)
*
|
2005-10-13 |
2013-05-21 |
The United States Of America As Represented By The Secretary Of Agriculture |
Methods to differentiate protein conformers
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
CA2627444A1
(en)
*
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
US7723477B2
(en)
*
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
ES2618785T3
(es)
*
|
2005-10-31 |
2017-06-22 |
Oncomed Pharmaceuticals, Inc. |
Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
RS53270B2
(sr)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
|
JP5475994B2
(ja)
|
2005-11-30 |
2014-04-16 |
アッヴィ・インコーポレイテッド |
抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
|
US20070149458A1
(en)
*
|
2005-12-06 |
2007-06-28 |
Amgen Inc. |
Uses of myostatin antagonists
|
ES2434494T3
(es)
|
2005-12-08 |
2013-12-16 |
Amgen, Inc. |
Células huésped mejoradas y métodos de cultivo
|
NZ568241A
(en)
|
2005-12-12 |
2011-08-26 |
Hoffmann La Roche |
Antibodies against amyloid beta 4 with glycosylation in the variable region
|
WO2007100937A2
(en)
*
|
2006-01-19 |
2007-09-07 |
The Regents Of The University Of Michigan |
System and method for spectroscopic photoacoustic tomography
|
WO2007102946A2
(en)
*
|
2006-01-23 |
2007-09-13 |
Amgen Inc. |
Crystalline polypeptides
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
AR059193A1
(es)
|
2006-01-31 |
2008-03-12 |
Bayer Schering Pharma Ag |
Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
DE602007009954D1
(de)
|
2006-03-22 |
2010-12-02 |
Viral Logic Systems Technology |
Verfahren zur identifizierung von polypeptid-targets
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
US20100034819A1
(en)
*
|
2006-03-31 |
2010-02-11 |
Centocor Inc. |
Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
|
MX2008012843A
(es)
|
2006-04-05 |
2009-01-19 |
Univ Rockefeller |
Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
|
EP2263696A1
(en)
*
|
2006-04-11 |
2010-12-22 |
CSL Behring GmbH |
Method of increasing the in vivo recovery of therapeutic polypeptides
|
JO3324B1
(ar)
*
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
CA2652570A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
US8377448B2
(en)
*
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
SG172698A1
(en)
*
|
2006-06-12 |
2011-07-28 |
Trubion Pharmaceuticals Inc |
Single-chain multivalent binding proteins with effector function
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
ES2376396T3
(es)
|
2006-06-26 |
2012-03-13 |
Amgen Inc. |
Método para tratar aterosclerosis.
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
MX341064B
(es)
|
2006-09-08 |
2016-08-05 |
Amgen Inc * |
Variantes de la familia il-1.
|
SG174782A1
(en)
*
|
2006-09-08 |
2011-10-28 |
Abbott Lab |
Interleukin - 13 binding proteins
|
JP2010504081A
(ja)
*
|
2006-09-08 |
2010-02-12 |
ジェネンテック インコーポレイテッド |
Wnt拮抗体ならびにwnt媒介障害の診断および処置におけるwnt拮抗体の使用
|
US20140147441A1
(en)
*
|
2006-09-12 |
2014-05-29 |
The General Hospital Corporation |
Compositions containing alpha-1-antitrypsin and methods for use
|
JP2010503687A
(ja)
*
|
2006-09-15 |
2010-02-04 |
ザ バーナム インスティチュート |
高親和性EphB受容体結合化合物とその使用法
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
CN101594878A
(zh)
|
2006-09-18 |
2009-12-02 |
雷普特药品公司 |
通过给予受体相关蛋白(rap)-缀合物对肝病症的治疗
|
EP2064300A4
(en)
*
|
2006-09-20 |
2013-05-22 |
Pneumrx Inc |
ADHESIVE FABRIC COMPOSITIONS AND RELATED METHODS
|
US20100034194A1
(en)
*
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
US20080123083A1
(en)
*
|
2006-11-29 |
2008-05-29 |
The Regents Of The University Of Michigan |
System and Method for Photoacoustic Guided Diffuse Optical Imaging
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
CA2708004C
(en)
*
|
2006-12-04 |
2015-12-01 |
Promedior, Inc. |
Conjoint therapy for treating fibrotic diseases
|
US20100166734A1
(en)
*
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
KR100888022B1
(ko)
|
2006-12-21 |
2009-03-09 |
재단법인 목암생명공학연구소 |
면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc
|
WO2008077616A1
(en)
|
2006-12-22 |
2008-07-03 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
WO2008095004A2
(en)
|
2007-01-31 |
2008-08-07 |
Affymax, Inc. |
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
|
EP2526962B1
(en)
|
2007-02-12 |
2019-08-14 |
CSL Behring GmbH |
Therapeutic application of Kazal-type serine protease inhibitors
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
DK2152736T3
(en)
|
2007-05-03 |
2017-09-18 |
Lysomab Gmbh |
Complement factor H-derived short-consensus repeat (SCR) antibody constructs
|
MX2009012343A
(es)
*
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
EP2738257A1
(en)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US20090175847A1
(en)
*
|
2007-05-30 |
2009-07-09 |
Abbott Laboratories |
Humanized antibodies to ab (20-42) globulomer and uses thereof
|
US20100260680A1
(en)
*
|
2007-06-05 |
2010-10-14 |
Oriental Yeast Co., Ltd. |
Novel bone mass increasing agent
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
US8497243B2
(en)
*
|
2007-07-06 |
2013-07-30 |
Promedior, Inc. |
Methods and compositions useful in the treatment of mucositis
|
US9884899B2
(en)
*
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
PT2489731E
(pt)
|
2007-07-26 |
2014-09-15 |
Amgen Inc |
Enzimas aciltransferase de lecitina-colesterol modificadas
|
US8293685B2
(en)
|
2007-07-26 |
2012-10-23 |
The Regents Of The University Of California |
Methods for enhancing bacterial cell display of proteins and peptides
|
WO2009012600A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
MX2010001363A
(es)
*
|
2007-08-09 |
2010-03-09 |
Syntonix Pharmaceuticals Inc |
Peptidos inmunomoduladores.
|
WO2009026122A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Amgen Inc. |
Formulations of antibodies and fc-fusion molecules using polycations
|
EP4248976A3
(en)
|
2007-08-23 |
2024-04-10 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US20100291086A1
(en)
*
|
2007-09-11 |
2010-11-18 |
Christopher Hovens |
Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
|
US8383114B2
(en)
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
AU2008308657A1
(en)
*
|
2007-10-02 |
2009-04-09 |
Potentia Pharmaceuticals, Inc. |
Sustained delivery of compstatin analogs from gels
|
US7829735B2
(en)
|
2007-10-26 |
2010-11-09 |
Northwestern University |
Universal phosphoramidite for preparation of modified biomolecules and surfaces
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
EP2235058A2
(en)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
EP4098661A1
(en)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US20140127200A1
(en)
*
|
2008-01-03 |
2014-05-08 |
The Scripps Research Institute |
Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
|
ES2500066T3
(es)
|
2008-01-25 |
2014-09-30 |
Amgen, Inc |
Anticuerpos frente a ferroportina y métodos de uso
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
CN101518644B
(zh)
*
|
2008-02-26 |
2011-07-13 |
上海交通大学医学院附属第九人民医院 |
Ang-2及其基因在制药中的应用
|
EP2626080A3
(en)
*
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjugated factor VIII molecules
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CA2722600C
(en)
|
2008-05-01 |
2014-01-21 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
US8293714B2
(en)
*
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
CN102089430B
(zh)
|
2008-05-09 |
2015-02-04 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
WO2009142460A2
(en)
*
|
2008-05-23 |
2009-11-26 |
Samsung Electronics Co., Ltd. |
Antibody-peptide fused synergibody
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
ES2531464T3
(es)
|
2008-06-24 |
2015-03-16 |
Csl Behring Gmbh |
Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
KR20110031369A
(ko)
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
BRPI0916326A2
(pt)
|
2008-07-23 |
2020-08-25 |
Hanmi Holdings Co., Ltd. |
complexo polipeptídico compreendendo polímero não-peptidil com três extremidades funcionais
|
WO2010014909A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
EP2168590A1
(en)
*
|
2008-09-24 |
2010-03-31 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Antimicrobial peptides
|
CN105079805A
(zh)
|
2008-09-26 |
2015-11-25 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
KR20170105124A
(ko)
|
2008-11-26 |
2017-09-18 |
암젠 인크 |
액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도
|
US20120121537A1
(en)
*
|
2009-01-12 |
2012-05-17 |
Chaomin Sun |
Methods and Compositions for Inhibiting Hepatitis C Virus Replication
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
JP2012516153A
(ja)
*
|
2009-01-29 |
2012-07-19 |
アボット・ラボラトリーズ |
Il−1結合タンパク質
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
US8283162B2
(en)
*
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
AU2010224172B2
(en)
*
|
2009-03-11 |
2016-01-21 |
Promedior, Inc. |
Treatment methods for autoimmune disorders
|
CA2754961C
(en)
*
|
2009-03-11 |
2018-04-10 |
Promedior, Inc. |
Treatment and diagnostic methods for hypersensitive disorders
|
US20120121591A1
(en)
|
2009-03-20 |
2012-05-17 |
Amgen Inc. |
SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
|
CA2749354A1
(en)
|
2009-03-30 |
2010-10-14 |
F. Hoffmann-La Roche Ag |
A method for avoiding glass fogging
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
KR101860572B1
(ko)
|
2009-05-05 |
2018-05-24 |
암젠 인크 |
Fgf21 돌연변이체 및 이의 용도
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
UA110323C2
(en)
*
|
2009-06-04 |
2015-12-25 |
Promedior Inc |
Derivative of serum amyloid p and their receipt and application
|
MX2011013457A
(es)
|
2009-06-15 |
2012-05-08 |
Biokine Therapeutics Ltd |
Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
|
HUE041034T2
(hu)
|
2009-06-17 |
2019-05-28 |
Promedior Inc |
SAP-variánsok és alkalmazásuk
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
CN102482321B
(zh)
|
2009-06-22 |
2015-06-17 |
安姆根有限公司 |
使用化学控制的氧化还原态重折叠蛋白质
|
JP2012531428A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
|
BRPI1015918A2
(pt)
|
2009-07-02 |
2019-09-24 |
Angiochem Inc |
conjugados de peptídeo multiméricos e usos dos mesmos
|
IT1395137B1
(it)
*
|
2009-08-05 |
2012-09-05 |
Spider Biotech S R L |
Nuovi peptidi antipatogeni
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
JP2013503607A
(ja)
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US20120183546A1
(en)
|
2009-09-23 |
2012-07-19 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
TW201121568A
(en)
*
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
PT3202898T
(pt)
|
2009-11-02 |
2018-12-28 |
Univ Washington |
Composições de nucleases terapêuticas e métodos
|
WO2011060372A2
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii b cell epitope variants having reduced immunogenicity
|
NZ600278A
(en)
*
|
2009-11-13 |
2014-04-30 |
Grifols Therapeutics Inc |
Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
|
MX2012005864A
(es)
|
2009-11-20 |
2012-08-31 |
Amgen Inc |
Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
|
WO2014121221A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an anti-activin-a compound to a subject
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP2510001B1
(en)
|
2009-12-08 |
2015-12-02 |
AbbVie Deutschland GmbH & Co KG |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
CN103124743A
(zh)
|
2009-12-29 |
2013-05-29 |
新兴产品开发西雅图有限公司 |
Ron结合构建物及其使用方法
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
AU2011207626B2
(en)
|
2010-01-19 |
2015-06-18 |
President And Fellows Of Harvard College |
Engineered opsonin for pathogen detection and treatment
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
KR101784539B1
(ko)
|
2010-01-28 |
2017-10-11 |
랩터 파마슈티컬스 인코포레이티드 |
수용체 결합 단백질(rap) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
|
CN102770450B
(zh)
|
2010-02-16 |
2015-12-02 |
诺沃—诺迪斯克有限公司 |
因子viii融合蛋白
|
RU2016146198A
(ru)
|
2010-03-02 |
2018-12-19 |
Эббви Инк. |
Терапевтические dll4-связывающие белки
|
US20130171128A1
(en)
|
2010-03-02 |
2013-07-04 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
NZ602548A
(en)
|
2010-03-03 |
2014-12-24 |
Univ British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
CN102971337B
(zh)
|
2010-04-01 |
2016-09-21 |
昂考梅德药品有限公司 |
卷曲蛋白结合药剂及其应用
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
AR081755A1
(es)
*
|
2010-04-02 |
2012-10-17 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
|
EP2927242A1
(en)
|
2010-04-09 |
2015-10-07 |
Amgen, Inc |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
ES2635594T3
(es)
|
2010-05-14 |
2017-10-04 |
Abbvie Inc. |
Proteínas de unión a IL-1
|
JP2013528599A
(ja)
|
2010-05-14 |
2013-07-11 |
アムジェン インコーポレイテッド |
増強デスレセプター・アゴニスト
|
CN102260343A
(zh)
|
2010-05-25 |
2011-11-30 |
健能隆医药技术(上海)有限公司 |
重组人g-csf二聚体在治疗神经损伤疾病中的用途
|
US20110305670A1
(en)
*
|
2010-06-10 |
2011-12-15 |
President And Fellows Of Harvard College |
Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
|
US8735548B2
(en)
|
2010-06-30 |
2014-05-27 |
Amgen Inc. |
Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
NZ607480A
(en)
|
2010-08-03 |
2014-10-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
EP2608803A4
(en)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
SG188591A1
(en)
|
2010-09-22 |
2013-04-30 |
Amgen Inc |
Carrier immunoglobulins and uses thereof
|
PL3241558T3
(pl)
|
2010-09-28 |
2021-08-30 |
Aegerion Pharmaceuticals, Inc. |
Wysoce rozpuszczalne leptyny
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
EP2668207A4
(en)
|
2011-01-24 |
2015-06-10 |
Univ Singapore |
LIPOARABINOMANNANE ANTIGEN-BINDING PROTEINS HAVING A MANNOSIS FROM PATHOGENIC MYCOBACTERIAS
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012109624A2
(en)
|
2011-02-11 |
2012-08-16 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
EP2681238A2
(en)
|
2011-02-28 |
2014-01-08 |
Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo |
Apoptosis-inducing molecules and uses therefor
|
EP2497489A1
(en)
|
2011-03-09 |
2012-09-12 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
|
US9352016B2
(en)
|
2011-03-09 |
2016-05-31 |
Csl Behring Gmbh |
Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
|
KR20140145947A
(ko)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Nav1.3과 nav1.7의 유효한 선별적 저해제
|
JP5908972B2
(ja)
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
KR101747489B1
(ko)
*
|
2011-04-25 |
2017-06-15 |
다이호야쿠힌고교 가부시키가이샤 |
pH 응답성 펩티드를 포함하는 나노 입자
|
IL300276A
(en)
|
2011-04-29 |
2023-04-01 |
Univ Washington |
Therapeutic nuclease preparations and methods
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
SG10201604564XA
(en)
|
2011-06-10 |
2016-07-28 |
Hanmi Science Co Ltd |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
JP6038905B2
(ja)
|
2011-06-17 |
2016-12-07 |
ハンミ サイエンス カンパニー リミテッド |
オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
|
EP2726088B1
(en)
|
2011-06-29 |
2019-01-02 |
Amgen Inc. |
Predictive biomarker of survival in the treatment of renal cell carcinoma
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
SG10201608671SA
(en)
|
2011-07-18 |
2016-12-29 |
Harvard College |
Engineered Microbe-Targeting Molecules and Uses Thereof
|
AU2012286048A1
(en)
|
2011-07-18 |
2014-02-20 |
Arts Biologics A/S |
Long acting luteinizing hormone (LH) compound
|
WO2013012855A1
(en)
|
2011-07-18 |
2013-01-24 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
IL230564B2
(en)
|
2011-07-22 |
2023-09-01 |
Csl Ltd |
Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
|
JP5947891B2
(ja)
|
2011-07-25 |
2016-07-06 |
ジェネロン(シャンハイ)コーポレイション リミテッドGeneron (Shanghai) Corporation Ltd. |
神経変性疾患を治療する医薬品の製造におけるg−csf二量体の応用
|
US9605083B2
(en)
|
2011-08-16 |
2017-03-28 |
Emory University |
JAML specific binding agents, antibodies, and uses related thereto
|
AU2012301713A1
(en)
*
|
2011-08-31 |
2014-03-06 |
Indi Molecular, Inc. |
VEGF-specific capture agents, compositions and methods of using and making
|
DE202012012998U1
(de)
|
2011-08-31 |
2014-06-13 |
Daniel Elias |
Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
|
JP2014529473A
(ja)
|
2011-09-02 |
2014-11-13 |
アムジエン・インコーポレーテツド |
医薬製品および医薬製品の露光を分析する方法
|
UY34346A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de fusión para tratar trastornos metabólicos
|
WO2013055958A1
(en)
|
2011-10-11 |
2013-04-18 |
Genentech, Inc. |
Improved assembly of bispecific antibodies
|
WO2013063114A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against tnf
|
EP2771361A1
(en)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Bispecific immunobinders directed against tnf and il-17
|
KR102091294B1
(ko)
|
2011-10-26 |
2020-04-16 |
암젠 인크 |
Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
|
CN102516393B
(zh)
*
|
2011-11-30 |
2017-03-15 |
北京康明百奥新药研发有限公司 |
胰岛素模拟肽融合蛋白和突变体及其应用
|
AU2012352168C1
(en)
|
2011-12-14 |
2018-01-25 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2793925B1
(en)
|
2011-12-19 |
2019-03-20 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
PL2794626T6
(pl)
|
2011-12-22 |
2020-11-02 |
Glycomimetics, Inc. |
Związki antagonistyczne E-selektyny
|
CN102558358A
(zh)
*
|
2011-12-30 |
2012-07-11 |
张海涛 |
人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
EP2806781B1
(en)
|
2012-01-23 |
2018-03-21 |
Washington University |
Goggle imaging systems and methods
|
PL2807192T3
(pl)
|
2012-01-27 |
2019-02-28 |
Abbvie Deutschland |
Kompozycja oraz sposób diagnostyki i leczenia chorób związanych ze zwyrodnieniem neurytów
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
DK2814502T3
(en)
|
2012-02-15 |
2017-12-18 |
Csl Behring Gmbh |
Von Willebrand Factor variants with improved Factor VIII binding affinity
|
US20150201588A1
(en)
|
2012-02-22 |
2015-07-23 |
Amgen Inc. |
Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
|
AU2013229063B2
(en)
|
2012-03-09 |
2016-10-06 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
*
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
AU2013239682B2
(en)
|
2012-03-28 |
2016-03-31 |
Amgen Inc. |
DR5 receptor agonist combinations
|
CA2871468C
(en)
*
|
2012-04-23 |
2021-09-21 |
Nrl Pharma, Inc. |
Lactoferrin fusion protein and method for preparation thereof
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
EP2846822A2
(en)
|
2012-05-11 |
2015-03-18 |
Prorec Bio AB |
Method for diagnosis and treatment of prolactin associated disorders
|
KR20220051197A
(ko)
|
2012-05-17 |
2022-04-26 |
익스텐드 바이오사이언시즈, 인크. |
개선된 약물 전달용 캐리어
|
BR112014031028A2
(pt)
|
2012-06-11 |
2017-08-15 |
Amgen Inc |
Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
JP6448056B2
(ja)
|
2012-07-19 |
2019-01-09 |
アムジェン インコーポレイテッド |
ヒトbtnl3タンパク質、核酸、および抗体、ならびにそれらの使用
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
US20150218236A1
(en)
*
|
2012-10-17 |
2015-08-06 |
Liverpool School Of Tropical Medicine |
Immunomodulatory proteins
|
WO2014066328A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
AR093387A1
(es)
|
2012-11-06 |
2015-06-03 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de proteina que comprende oxintomodulina y un fragmento de inmunoglobulina
|
PL2928476T3
(pl)
|
2012-12-07 |
2018-07-31 |
Glycomimetics, Inc. |
Związki, kompozycje i sposoby wykorzystujące antagonistów e-selektyny do mobilizacji komórek hematopoietycznych
|
US20160067347A1
(en)
*
|
2012-12-20 |
2016-03-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
WO2014110503A1
(en)
*
|
2013-01-11 |
2014-07-17 |
Case Western Reserve University |
Methods and compositions for treating cancer
|
KR102073748B1
(ko)
|
2013-01-31 |
2020-02-05 |
한미약품 주식회사 |
재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
|
CN105073195A
(zh)
|
2013-02-04 |
2015-11-18 |
昂科梅德制药有限公司 |
使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
|
EP3616727B1
(en)
*
|
2013-02-26 |
2021-03-31 |
Hanmi Pharm. Co., Ltd. |
Insulin analog conjugates and use thereof
|
US9701729B2
(en)
*
|
2013-03-08 |
2017-07-11 |
Taiho Pharmaceutical Co., Ltd. |
Peptide having 5 linked CTL epitopes
|
US10286047B2
(en)
|
2013-03-08 |
2019-05-14 |
Csl Behring Gmbh |
Treatment and prevention of remote ischemia-reperfusion injury
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
PT2968461T
(pt)
|
2013-03-13 |
2022-12-26 |
Genzyme Corp |
Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
WO2014144325A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Methods and compositions for improving detection and/or capture of a target entity
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
JP6649250B2
(ja)
*
|
2013-05-21 |
2020-02-19 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
操作されたヘム結合性構成物およびその使用
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
WO2014207199A1
(en)
|
2013-06-28 |
2014-12-31 |
Csl Behring Gmbh |
Combination therapy using a factor xii inhibitor and a c1-inhibitor
|
MX2016001020A
(es)
|
2013-07-25 |
2016-08-03 |
Novartis Ag |
Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
|
TW201518323A
(zh)
|
2013-07-25 |
2015-05-16 |
Novartis Ag |
合成apelin多肽之生物結合物
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
KR102285939B1
(ko)
*
|
2013-09-18 |
2021-08-05 |
비씨엔 펩티드즈, 에스. 에이. |
염증성 및/또는 면역 질환의 치료를 위한 코르티스타틴 유사체
|
US20160228569A1
(en)
*
|
2013-10-15 |
2016-08-11 |
S. Kenny Roberts |
Peptide constructs and well-defined aggregates thereof
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
RU2636549C1
(ru)
*
|
2013-10-21 |
2017-11-23 |
Тайхо Фармасьютикал Ко., Лтд. |
Новый пептид, имеющий 4 связанных ctl-эпитопа
|
DK3063275T3
(da)
|
2013-10-31 |
2019-11-25 |
Resolve Therapeutics Llc |
Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
|
US10513546B2
(en)
|
2013-12-18 |
2019-12-24 |
President And Fellows Of Harvard College |
CRP capture/detection of gram positive bacteria
|
AU2015205327B2
(en)
|
2014-01-09 |
2019-02-14 |
Hadasit Medical Research Services And Development Ltd. |
Improved cell compositions and methods for cancer therapy
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
HUE041976T2
(hu)
*
|
2014-04-11 |
2019-06-28 |
Medimmune Llc |
Cisztein-módosított ellenanyagokat tartalmazó konjugált vegyületek
|
HRP20231139T1
(hr)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
|
US20160002326A1
(en)
|
2014-06-10 |
2016-01-07 |
Abbvie Inc. |
Compositions and methods for treating rheumatoid arthritis
|
ES2950789T3
(es)
|
2014-06-10 |
2023-10-13 |
Amgen Inc |
Polipéptidos de apelina
|
BR112016029624A2
(pt)
|
2014-06-18 |
2017-10-24 |
Csl Behring Gmbh |
terapia usando um inibidor do fator xii em um distúrbio neurotraumático
|
BR112016030950A2
(pt)
|
2014-07-02 |
2018-03-27 |
Csl Ltd |
polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
|
US10526391B2
(en)
|
2014-07-22 |
2020-01-07 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
AR101875A1
(es)
|
2014-09-15 |
2017-01-18 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
JP6749898B2
(ja)
|
2014-10-15 |
2020-09-02 |
アムジエン・インコーポレーテツド |
宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
|
EP3220961B1
(en)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
AU2015335743B2
(en)
|
2014-10-23 |
2020-12-24 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
DK3237614T3
(da)
*
|
2014-12-22 |
2019-09-09 |
Lanthiopep Bv |
Nye fremgangsmåder til fremvisning af cyklisk peptider på overfladen af bakteriofagpartikler
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
US20160244520A1
(en)
|
2015-01-24 |
2016-08-25 |
Abbvie Inc. |
Compositions and methods for treating psoriatic arthritis
|
EP3250240A4
(en)
*
|
2015-01-30 |
2018-10-10 |
University of Utah Research Foundation |
Dimeric collagen hybridizing peptides and methods of using
|
RU2723045C2
(ru)
|
2015-02-19 |
2020-06-08 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их получения
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
CN107428844A
(zh)
*
|
2015-03-05 |
2017-12-01 |
发展生物工程与基因技术的彼得和特劳德尔·恩格尔霍恩基金会 |
用于将肽呈递在细胞表面上的系统
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
US10857229B2
(en)
|
2015-04-30 |
2020-12-08 |
Amgen Inc. |
Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
US10806804B2
(en)
|
2015-05-06 |
2020-10-20 |
Washington University |
Compounds having RD targeting motifs and methods of use thereof
|
CA2986626A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
WO2016188905A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
US10980892B2
(en)
|
2015-06-15 |
2021-04-20 |
Angiochem Inc. |
Methods for the treatment of leptomeningeal carcinomatosis
|
WO2016209972A1
(en)
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
WO2017024114A1
(en)
|
2015-08-06 |
2017-02-09 |
President And Fellows Of Harvard College |
Improved microbe-binding molecules and uses thereof
|
EP3350216A1
(en)
|
2015-09-15 |
2018-07-25 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
MY197562A
(en)
|
2015-09-21 |
2023-06-23 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
CA3000697A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
KR102146319B1
(ko)
|
2015-10-02 |
2020-08-25 |
에프. 호프만-라 로슈 아게 |
Pd1 및 tim3에 특이적인 이중특이성 항체
|
WO2017075189A1
(en)
|
2015-10-27 |
2017-05-04 |
University Of Massachusetts |
Factor h-fc immunotherapy
|
KR101826792B1
(ko)
*
|
2015-10-29 |
2018-02-09 |
주식회사 와이바이오로직스 |
Dlk1의 세포 외 수용성 도메인을 유효성분으로 포함하는 지방간 또는 인슐린 저항성 증후군 예방 및 치료용 조성물
|
EP3390447A1
(en)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
MX2018007307A
(es)
*
|
2015-12-15 |
2019-03-14 |
Sarepta Therapeutics Inc |
Conjugados de peptidos y oligonucleotidos.
|
AU2016371466B2
(en)
|
2015-12-17 |
2020-04-09 |
Alonbio Ltd |
Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
|
US10646465B2
(en)
|
2015-12-17 |
2020-05-12 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
EP3184149A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Soluble glycoprotein v for treating thrombotic diseases
|
AU2017205776B2
(en)
|
2016-01-07 |
2020-09-10 |
CSL Behring Lengnau AG |
Mutated von Willebrand factor
|
SG10201912498YA
(en)
|
2016-01-07 |
2020-02-27 |
CSL Behring Lengnau AG |
Mutated truncated von willebrand factor
|
AU2017247004B2
(en)
|
2016-04-06 |
2022-07-07 |
Csl Limited |
Method of treating atherosclerosis
|
JP6600405B2
(ja)
*
|
2016-04-07 |
2019-10-30 |
インダストリー−ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス |
新血管生成抑制のための血管内皮成長因子受容体ターゲッティングペプチド−エラスチン融合ポリペプチド及び自己組立ナノ構造体
|
WO2017179647A1
(ja)
*
|
2016-04-14 |
2017-10-19 |
Taoヘルスライフファーマ株式会社 |
アミロスフェロイド(aspd)結合阻害ペプチド、並びに評価及びスクリーニング方法
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール.ピー.シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
PL3458479T3
(pl)
|
2016-06-08 |
2021-07-26 |
Abbvie Inc. |
Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
|
US20190241878A1
(en)
|
2016-07-01 |
2019-08-08 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
CA3218290A1
(en)
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
WO2018032638A1
(zh)
|
2016-08-19 |
2018-02-22 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
MA46466A
(fr)
|
2016-10-06 |
2019-08-14 |
Amgen Inc |
Formulations pharmaceutiques de protéines à viscosité réduite
|
WO2018079702A1
(ja)
|
2016-10-28 |
2018-05-03 |
株式会社Nrlファーマ |
ラクトフェリン/アルブミン融合タンパク質及びその製造方法
|
WO2018087267A1
(en)
|
2016-11-11 |
2018-05-17 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
SG10201912768YA
(en)
|
2016-11-11 |
2020-02-27 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
CN108367075B
(zh)
|
2016-11-23 |
2022-08-09 |
免疫方舟医药技术股份有限公司 |
4-1bb结合蛋白及其用途
|
WO2018102777A1
(en)
*
|
2016-12-01 |
2018-06-07 |
University Of South Florida |
Peptibodies, compositions thereof, and methods of treating atrial fibrillation
|
WO2018132768A1
(en)
|
2017-01-13 |
2018-07-19 |
Sanna Pietro P |
Methods and compositions for treating hpa hyperactivity
|
US10183070B2
(en)
|
2017-01-31 |
2019-01-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
WO2018174668A2
(ko)
|
2017-03-23 |
2018-09-27 |
한미약품 주식회사 |
인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
|
PE20191494A1
(es)
*
|
2017-04-03 |
2019-10-21 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
KR20200018690A
(ko)
|
2017-06-22 |
2020-02-19 |
체에스엘 베링 렝나우 아게 |
절단된 vwf에 의한 fviii 면역원성의 조절
|
BR112020001180A2
(pt)
|
2017-07-20 |
2020-09-08 |
Aptevo Research And Development Llc |
proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados
|
CA3070442A1
(en)
|
2017-07-26 |
2019-01-31 |
Janssen Pharmaceutica Nv |
Methods of protecting vascular integrity induced by targeted radiation therapy
|
WO2019028012A2
(en)
|
2017-07-31 |
2019-02-07 |
Dana-Farber Cancer Institute, Inc. |
METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
|
EP3661562A1
(en)
|
2017-08-04 |
2020-06-10 |
Amgen Inc. |
Method of conjugation of cys-mabs
|
CN111164104A
(zh)
|
2017-08-09 |
2020-05-15 |
麻省理工学院 |
白蛋白结合肽缀合物及其方法
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
CA3067735A1
(en)
|
2017-08-17 |
2019-02-21 |
Just Biotherapeutics, Inc. |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
CN111315767A
(zh)
|
2017-08-22 |
2020-06-19 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
KR20200101954A
(ko)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항원-아주반트 커플링 시약 및 사용 방법
|
WO2019190293A1
(ko)
*
|
2018-03-30 |
2019-10-03 |
한미약품 주식회사 |
뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
|
AU2019365102A1
(en)
|
2018-10-23 |
2021-04-29 |
Amgen Inc. |
Automatic calibration and automatic maintenance of Raman spectroscopic models for real-time predictions
|
EP3873488A4
(en)
|
2018-10-31 |
2022-08-03 |
The University of Sydney |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
|
SG11202106686PA
(en)
|
2019-01-04 |
2021-07-29 |
Resolve Therapeutics Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
CA3125552A1
(en)
*
|
2019-01-07 |
2020-07-16 |
Cenna Biosciences Inc. |
Novel peptides and uses thereof
|
MX2021008942A
(es)
|
2019-01-25 |
2021-08-24 |
Janssen Pharmaceutica Nv |
Metodos para mitigar efectos toxicos vesicantes y gas caustico.
|
KR20210119469A
(ko)
|
2019-01-25 |
2021-10-05 |
잔센파마슈티카엔.브이. |
전신 방사선/화학 노출에 대응한 장기 및 혈관 손상에 대한 보호, 조혈 회복 및 생존을 증진시키는 방법
|
AU2020211412A1
(en)
|
2019-01-25 |
2021-08-12 |
Janssen Pharmaceutica Nv |
Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
|
CN116063505A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
US20220119757A1
(en)
|
2019-02-15 |
2022-04-21 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
CN114144433A
(zh)
|
2019-03-22 |
2022-03-04 |
反射制药有限公司 |
用于目标蛋白的多价d-肽化合物
|
JP2022521353A
(ja)
|
2019-03-22 |
2022-04-06 |
リフレクション ファーマシューティカルズ, インコーポレイテッド |
Vegfのためのd-ペプチド性化合物
|
BR112021022775A2
(pt)
|
2019-05-15 |
2022-02-01 |
Alonbio Ltd |
Moléculas pequenas para tratamento do câncer, inibição da atividade da quimiocina e/ou indução da morte celular
|
BR112021022940A2
(pt)
|
2019-05-17 |
2022-01-18 |
Csl Behring Ag |
Haptoglobina para uso no tratamento de um resultado neurológico secundário após um acidente vascular cerebral hemorrágico
|
CA3141690A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
CN114072420A
(zh)
|
2019-07-04 |
2022-02-18 |
康诺贝林伦瑙有限公司 |
用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
JP2023500953A
(ja)
|
2019-11-11 |
2023-01-11 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
第viii因子に対する寛容を誘導するためのポリペプチド
|
EP4072598A4
(en)
|
2019-12-13 |
2024-02-21 |
Washington University St Louis |
NEAR-INFRARED FLUORESCENT DYES, FORMULATIONS AND ASSOCIATED METHODS
|
WO2021145946A1
(en)
*
|
2020-01-13 |
2021-07-22 |
Invenra Inc. |
Multispecific treg binding molecules
|
EP4090367A1
(en)
|
2020-01-13 |
2022-11-23 |
T-Mobile USA, Inc. |
Pattern recognition based on millimeter wave transmission in wireless communication networks
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
MX2023002125A
(es)
|
2020-08-20 |
2023-04-26 |
Amgen Inc |
Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
|
EP4225786A2
(en)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
EP4244246A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
CN116568327A
(zh)
|
2020-11-20 |
2023-08-08 |
德国杰特贝林生物制品有限公司 |
治疗抗体介导的排斥反应的方法
|
IL303328A
(en)
|
2020-12-01 |
2023-07-01 |
Aptevo Res & Development Llc |
CD3-binding bispecific and heterodimeric antibodies to PSMA
|
EP4263568A1
(en)
|
2020-12-18 |
2023-10-25 |
Richter Gedeon Nyrt. |
Methods for the purification of refolded fc-peptide fusion protein
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024504822A
(ja)
|
2021-02-01 |
2024-02-01 |
ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト |
出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法
|
CN117651714A
(zh)
|
2021-04-20 |
2024-03-05 |
美国安进公司 |
多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
|
WO2022234070A1
(en)
|
2021-05-07 |
2022-11-10 |
Csl Behring Ag |
Expression system for producing a recombinant haptoglobin (hp) beta chain
|
EP4341291A1
(en)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosing regimens for protein therapeutics
|
WO2022266467A2
(en)
|
2021-06-17 |
2022-12-22 |
Dana-Farber Cancer Institute, Inc. |
Recombinant histone polypeptide and uses thereof
|
WO2023056444A1
(en)
|
2021-10-01 |
2023-04-06 |
Janssen Pharmaceutica N.V. |
Methods of increasing progenitor cell production
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
TW202326113A
(zh)
|
2021-10-27 |
2023-07-01 |
美商安進公司 |
使用光譜學進行的基於深度學習的預測
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
WO2023180525A1
(en)
|
2022-03-24 |
2023-09-28 |
Richter Gedeon Nyrt. |
Method for the manufacture of biopharmaceuticals
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024047219A1
(en)
|
2022-09-02 |
2024-03-07 |
Csl Behring Ag |
Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
|